Leaflet ROBINUL-NEOSTIGMINE 0.5mg / ml 2.5mg / ml solution for injection


Indicated for: asthma; chronic obstructive pulmonary disease

Route of administration: injectable

Substance: glycopyrronium bromide + neostigmine methylsulfate (bronchodilators)

ATC: A03AB02 (Alimentary tract and metabolism | Drugs for functional gastrointestinal disorders | Synthetic anticholinergics, quaternary ammonium compounds)

Glycopyrronium bromide + neostigmine methylsulfate is a combination of medications used to reverse the effects of muscle relaxants administered during surgery. It helps restore normal muscle function after general anesthesia.

Glycopyrronium bromide is an anticholinergic agent that reduces side effects such as excessive secretions or bradycardia (slowed heart rate) caused by neostigmine. Neostigmine methylsulfate is a cholinesterase inhibitor that increases acetylcholine levels, aiding in the restoration of muscle contraction.

This combination is effective and well-tolerated but may cause side effects such as dry mouth, nausea, dizziness, or changes in heart rate. It is important for the medication to be administered under strict medical supervision, usually in a hospital setting.

General data about ROBINUL-NEOSTIGMINE 0.5mg / ml 2.5mg / ml

  • Substance: glycopyrronium bromide + neostigmine methylsulfate
  • Date of last drug list: 01-12-2025
  • Commercial code: W69292001
  • Concentration: 0.5mg / ml 2.5mg / ml
  • Pharmaceutical form: solution for injection
  • Quantity: 10
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: EUMEDICA PHARMACEUTICALS GMBH - GERMANIA
  • Holder: CN UNIFARM S.A. - ROMANIA
  • Number: 765/2022/01